Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501845 | 0.86 | APLNR (0.80) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL3778963 | 0.83 | APLNR (0.48) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL301531 | 0.81 | — | — | |
| SCHEMBL225096 | 0.81 | APLNR (0.46) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL3129361 | 0.81 | APLNR (0.46) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL532643 | 0.80 | APLNR (0.47) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL3828406 | 0.79 | APLNR (0.45) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL3824303 | 0.79 | APLNR (0.45) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL3825092 | 0.79 | APLNR (0.45) | APLNRLMNAPPP1CAALDH1A1CYP2C19 | |
| SCHEMBL3825088 | 0.79 | APLNR (0.45) | APLNRLMNAPPP1CAALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107949549-A | Novel shrinkage reducing agent for inorganic binder | 赢创德固赛有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-107949549-A | Novel shrinkage reducing agent for inorganic binder | 赢创德固赛有限公司 | 2018-04-20 | — | — | CN | disclosed |
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-4948790-A | Long-acting androgenic compounds and pharmaceutical compositions thereof | ARCHER SYDNEY (US) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | APLNR 2976/4885LMNA 2154/4885PPP1CA 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.